ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 13 February 2009

Endocrine-Related Cancer 2009;16:537.

DOI: 10.1677/ERC-09-0008
Copyright © 2009 by the Society for Endocrinology.
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
ERC-09-0008v1
ERC-09-0008v2
ERC-09-0008v3
16/2/537    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Revill, K.
Right arrow Articles by Farrell, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Revill, K.
Right arrow Articles by Farrell, W.

RESEARCH

Loss of NNAT expression is associated with promoter hypermethylation in pituitary adenoma

Kate Revill, Kevin Dudley, Anne-Marie McNicol, Richard Clayton and William Farrell

K Revill, ISTM, Keele University, Stoke-on-Trent, United Kingdom
K Dudley, ISTM, Keele University, Stoke-on-Trent, United Kingdom
A McNicol, Molecular and Cellular Pathology, The University of Queensland, Brisbane, Australia
R Clayton, Dept of Medicine, University of Keele, North Staffordshire Hospital Centre, stoke, United Kingdom
W Farrell, ISTM, Keele University, Stoke-on-Trent, United Kingdom

Correspondence: William Farrell, Email: w.e.farrell{at}keele.ac.uk

Abstract

The imprinted gene, Neuronatin (NNAT), is one of the most abundant transcripts in the pituitary and is thought to be involved in the development and maturation of this gland. In a recent whole-genome approach, exploiting a pituitary tumour cell line, we identified hypermethylation associated loss of NNAT. In this report we determined the expression pattern of NNAT in individual cell types of the normal gland and within each of the different pituitary adenoma subtypes. In addition, we determined associations between expression and CpG island methylation and used colony forming efficiency assays (CFE) to gain further insight into the tumour-suppressor function of this gene. Immunohistochemical (IHC) co-localisation studies of normal pituitaries showed that each of the hormone secreting cells (Growth hormone-GH, Prolactin-PRL, Adrenocorticotroph hormone-ACTH, Follicle stimulating hormone-FSH and Thyroid stimulating hormone-TSH) expressed NNAT. However, 33 of 47 adenomas comprising, 11 somatotrophinomas, 10 prolactinomas, 12 corticotrophinomas and 14 non-functioning tumours, irrespective of subtype failed to express either NNAT transcript or protein as determined by RT-qPCR and IHC respectively. In normal pituitaries and adenomas that expressed NNAT the promoter-associated CpG island showed characteristics of an imprinted gene where ~50% of molecules were densely methylated. However, in the majority of adenomas that showed loss or significantly reduced expression of NNAT relative to normal pituitaries the gene-associated CpG island showed significantly increased methylation. Induced expression of NNAT in transfected AtT20 cells significantly reduced CFE. Collectively these findings point to an important role for NNAT in the pituitary and perhaps tumour development in this gland.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the Society for Endocrinology.